

**REMARKS**

Reconsideration of this application is requested. Claims 1-5, 8 and 12-15 are active in the application subsequent to entry of this amendment.

The claims have been amended in order to more particularly point out and distinctly claim that which applicants regard as their invention and to present them in more traditional format. Appropriate Markush terminology has been included in claims 2-4, claims 6 and 7 withdrawn as being non-statutory and claims 9-11 rewritten in method of treatment format.


Item 1 of the Official Action requires an election of species<sup>not</sup> as to a specific combination of ingredients and instructs counsel to include claims directed to the selected combination. Applicants elect, with traverse, the combination of propionyl L-carnitine and simvastatin which is consistent with the clinical study reported in the description of the invention of this application. To this end, the examiner will note that claim 5 is directed to a composition containing these two components while method of treatment claim 15 is directed to the same combination of elected components.

Please examine all of the claims now in this application on the basis of the above amendments taking into account the Information Disclosure Statement filed July 28, 2000.

Respectfully submitted,

**NIXON & VANDERHYE P.C.**

By: \_\_\_\_\_

  
Arthur R. Crawford  
Reg. No. 25,327

ARC:pfc  
1100 North Glebe Road, 8th Floor  
Arlington, VA 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100